var data={"title":"Eflornithine (United States: Availability of intravenous preparation limited to CDC and WHO distribution programs): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Eflornithine (United States: Availability of intravenous preparation limited to CDC&nbsp;and&nbsp;WHO distribution programs): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6095?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-drug-information\" class=\"drug drug_general\">see &quot;Eflornithine (United States: Availability of intravenous preparation limited to CDC&nbsp;and&nbsp;WHO distribution programs): Drug information&quot;</a> and <a href=\"topic.htm?path=eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-patient-drug-information\" class=\"drug drug_patient\">see &quot;Eflornithine (United States: Availability of intravenous preparation limited to CDC&nbsp;and&nbsp;WHO distribution programs): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164442\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Vaniqa</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3011945\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Vaniqa</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1010462\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiprotozoal</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Topical Skin Product</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1010489\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-drug-information\" class=\"drug drug_general\">see &quot;Eflornithine (United States: Availability of intravenous preparation limited to CDC&nbsp;and&nbsp;WHO distribution programs): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Reduction of unwanted facial hair:</b> Topical: Cream: Female Children &ge;12 years and Adolescents: Apply thin layer of cream to affected areas of face and adjacent chin twice daily, at least 8 hours apart </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Treatment of infections caused by <i>Trypanosoma brucei gambiense</i> infection (sleeping sickness):</b> Limited data available (WHO, 2013): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">NECT regimen: Children and Adolescents: IV: 200 mg/kg/dose every 12 hours for 7 days in combination with nifurtimox  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Monotherapy: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &lt;12 years: 150 mg/kg/dose every 6 hours for 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: 100 mg/kg/dose every 6 hours for 14 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Reduction unwanted facial hair:</b> Topical: Apply thin layer of cream to affected areas of face and adjacent chin twice daily, at least 8 hours apart </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection: Dose should be adjusted although no specific guidelines are available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Topical: There are no dosage adjustments provided in manufacturer's labeling; however, dosage adjustment unlikely due to limited systemic absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Topical: There are no dosage adjustments provided in manufacturer's labeling; however, dosage adjustment unlikely due to limited systemic absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164426\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vaniqa: 13.9% (45 g) [contains cetearyl alcohol, methylparaben, propylparaben]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164411\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15837501\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Injectable eflornithine is donated to World Health Organization (WHO) by the manufacturer. Further information may be found on WHO website at http://www.who.int/trypanosomiasis_african/diagnosis/en/index.html or by contacting the CDC Drug Service (404-639-3670). Additional information from the CDC is available at https://www.cdc.gov/laboratory/drugservice/formulary.html.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1010494\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: IV: Administer diluted solution by IV infusion over 45 to 120 minutes; not for IM administration </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical: For external use only. Rub in thoroughly. Hair removal techniques must still be continued; wait at least 5 minutes after removing hair to apply cream. Do not wash affected area for at least 8 hours following application. Makeup and sunscreen may be used over treated area(s) after cream has dried.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164439\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream: Store at controlled room temperature 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59 &deg;F to 86&deg;F); do not freeze. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection: Use within 24 hours of preparation. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1010463\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Reduce unwanted hair from face and adjacent areas under the chin (Cream: FDA approved in females &ge;12 years and adults); injectable (available through WHO). Used for treatment of meningoencephalitic stage of <i>Trypanosoma brucei gambiense</i> infection (sleeping sickness). <b>Note:</b> Eflornithine has specific activity against <i>T.b. gambiense</i> in early and late stages (not effective for <i>T.b. rhodesiense</i>). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164466\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Vaniqa may be confused with Viagra</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164464\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Injection (Priotto 2009):</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac arrhythmia, chest pain, edema, hypertension, hypotension, shock</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Amnesia, anxiety, ataxia, coma, confusion, depression, dizziness, hallucination, headache, insomnia, lethargy, peripheral neuropathy, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Dehydration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dysgeusia, dysphagia, hiccups, nausea, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Change in creatinine, urinary frequency, urinary incontinence, urinary urgency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, leukopenia, neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal bilirubin levels, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Extravasation, injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, myalgia, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Inner ear disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, dyspnea, epistaxis, respiratory distress</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Topical:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, headache, tingling of skin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris, alopecia, burning sensation of skin, erythema, folliculitis, ingrown hair, pruritus, pseudofolliculitis barbae, skin irritation, skin rash, stinging of the skin, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, dyspepsia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acne rosacea, cheilitis, contact dermatitis, dermal hemorrhage, facial edema, herpes simplex infection, nausea, numbness, swelling of lips, vertigo, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164431\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to eflornithine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164415\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cream: Appropriate use: For topical use by females only; discontinue if hypersensitivity occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: For IV use only; not for IM administration. Must be diluted before use; frequent monitoring for myelosuppression should be done; use with caution in patients with a history of seizures and in patients with renal impairment; serial audiograms should be obtained; due to the potential for relapse, patients should be followed up for at least 24 months.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299255\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164420\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=98583&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164422\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164434\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">When administered topically, teratogenic effects were not observed in animal reproduction studies. Discontinuation or not initiating therapy should be considered since information related to topical use in pregnancy is limited.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1010497\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: CBC with platelet counts </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164414\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream: Eflornithine inhibits the enzyme ornithine decarboxylase (ODC) which inhibits cell division and synthetic functions and thereby affects the rate of hair growth.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Eflornithine exerts antitumor and antiprotozoal effects through specific, irreversible (&ldquo;suicide&rdquo;) inhibition of the enzyme ornithine decarboxylase (ODC). ODC is the rate-limiting enzyme in the biosynthesis of putrescine, spermine, and spermidine, the major polyamines in nucleated cells. Polyamines are necessary for the synthesis of DNA, RNA, and proteins and are, therefore, necessary for cell growth and differentiation. Although many microorganisms and higher plants are able to produce polyamines from alternate biochemical pathways, all mammalian cells depend on ornithine decarboxylase to produce polyamines. Eflornithine inhibits ODC and rapidly depletes animal cells of putrescine and spermidine; the concentration of spermine remains the same or may even increase. Rapidly dividing cells appear to be most susceptible to the effects of eflornithine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164430\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Decreased hair growth: 4-8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration of action: Decreased hair growth: Continues until ~8 weeks after discontinuing treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Topical: &lt;1% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IV: 3-3.5 hours; Topical: 8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily urine (as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164433\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Vaniqa External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">13.9% (45 g): $199.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164435\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Vaniqa (AU, BE, CZ, DE, DK, ES, FR, GB, HR, HU, IE, IL, IS, IT, LB, LT, MT, NL, NO, NZ, PL, PT, RO, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Drugs for Parasitic Infections,&rdquo; <i>Med Lett Drugs Ther</i>, 1993, 35(911):111-22. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-pediatric-drug-information/abstract-text/8246830/pubmed\" target=\"_blank\" id=\"8246830\">8246830</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haegele KD, Alken RG, Grove J, et al, &ldquo;Kinetics of &alpha;-Difluoromethylornithine: An Irreversible Inhibitor of Ornithine Decarboxylase,&rdquo; <i>Clin Pharmacol Ther</i>, 1981, 30(2):210-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-pediatric-drug-information/abstract-text/6788425/pubmed\" target=\"_blank\" id=\"6788425\">6788425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kappagoda S, Singh U, and Blackburn BG, &quot;Antiparasitic Therapy,&quot; <i>Mayo Clin Proc</i>, 2011, 86(6):561-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-pediatric-drug-information/abstract-text/21628620/pubmed\" target=\"_blank\" id=\"21628620\">21628620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lapidoth M, Dierickx C, Lanigan S, et al, &quot;Best Practice Options for Hair Removal in Patients With Unwanted Facial Hair Using Combination Therapy With Laser: Guidelines Drawn Up by an Expert Working Group,&quot; <i>Dermatology</i>, 2010, 221(1):34-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-pediatric-drug-information/abstract-text/20587996/pubmed\" target=\"_blank\" id=\"20587996\">20587996</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Priotto G, Kasparian S, Mutombo W, et al, &quot;Nifurtimox-Eflornithine Combination Therapy for Second-Stage African <i>Trypanosoma brucei gambiense</i> Trypanosomiasis: A Multicenter, Randomized, Phase III, Non-Inferiority Trial,&quot; <i>Lancet</i>, 2009, 374(9683):56-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-pediatric-drug-information/abstract-text/19559476/pubmed\" target=\"_blank\" id=\"19559476\">19559476</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steverding D, &quot;The Development of Drugs for Treatment of Sleeping Sickness: A Historical Review,&quot; <i>Parasit Vectors</i>, 2010, 3(1):15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-pediatric-drug-information/abstract-text/20219092/pubmed\" target=\"_blank\" id=\"20219092\">20219092</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vaniqa (eflornithine) [prescribing information]. Carlsbad, CA: SkinMedica; July 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Clinical guidelines. Diagnosis and treatment manual for curative programmes in hospilals and dispensaries. Guidance for prescribing. March 2013. Available at http://apps.who.int/medicinedocs/documents/s17078e/s17078e.pdf. Date accessed: November 7, 2014. </div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 98583 Version 31.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F164442\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F3011945\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1010462\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1010489\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F164426\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F164411\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F15837501\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1010494\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F164439\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1010463\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F164466\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F164464\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F164431\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F164415\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299255\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F164420\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F164422\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F164434\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1010497\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F164414\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F164430\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F164433\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F164435\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/98583|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-drug-information\" class=\"drug drug_general\">Eflornithine (United States: Availability of intravenous preparation limited to CDC&nbsp;and&nbsp;WHO distribution programs): Drug information</a></li><li><a href=\"topic.htm?path=eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-patient-drug-information\" class=\"drug drug_patient\">Eflornithine (United States: Availability of intravenous preparation limited to CDC&nbsp;and&nbsp;WHO distribution programs): Patient drug information</a></li></ul></div></div>","javascript":null}